全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

A High Sensitive LC-MS/MS Method for the Simultaneous Determination of Potential Genotoxic Impurities Carboxy Phenyl Boronic Acid and Methyl Phenyl Boronic Acid in Lumacaftor

DOI: 10.4236/ajac.2021.123006, PP. 74-86

Keywords: Boronic Acid, Genotoxic, LC-MS/MS, Lumacaftor

Full-Text   Cite this paper   Add to My Lib

Abstract:

A simple, rapid, and highly sensitive LC-MS/MS method has been developed for the simultaneous and trace level quantification of underivatized boronic acids in lumacaftor active pharmaceutical ingredient. Chromatographic separation of boronic acids and lumacaftor achieved using Agilent Poroshell HPH C18 150 × 4.6 mm 2.7 μ column with 0.1% ammonia in water as mobile phase A and 100% acetonitrile as mobile phase B at a flow rate of 0.25 ml/min. Gradient elution was used with a total method run time of 14 minutes. Boronic acids were successfully ionized and quantified without derivatization using electrospray ionization in negative mode using tandem quadrupole mass spectrometry in multiple reactions monitoring mode. Method validation was performed as per ICH guidelines with good linearity over the concentration range of 0.05 ppm to 5 ppm of Lumacaftor test concentration for both the boronic acids with a correlation coefficient of >0.99. Recoveries were found good at different concentration levels and within the range of 80% - 120%. The developed method can be successfully used for the routine quantification of boronic acids at a concentration level of 20 ng/ml (1 ppm with respect to 20 mg/ml lumacaftor).

References

[1]  Miyuara, N. and Suzuki, A. (1995) Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds. Chemical Reviews, 95, 2457-2483.
https://doi.org/10.1021/cr00039a007
[2]  Hansen, M.M., Jolly, R.A. and Lynder, R.J. (2015) Boronic Acids and Derivatives-Probing the Structure-Activity Relationships for Mutagenicity. Organic Process Research & Developments, 19, 1507-1516.
https://doi.org/10.1021/acs.oprd.5b00150
[3]  Ames, B.N., Lee, F.D. and Durston, W.E. (1973) An Improved Bacterial Test System for the Detection and Classification of Mutagens and Carcinogens. Proceedings of the National Academy of Sciences of the United States of America, 70, 782-786.
https://doi.org/10.1073/pnas.70.3.782
[4]  ICH M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk.
https://database.ich.org/sites/default/files/M7_R1_Guideline.pdf
[5]  Cholon, D.M., Esther Jr., C.R. and Gentzsch, M. (2016) Efficacy of Lumacaftor-Ivacaftor for the Treatment of Cystic Fibrosis Patients Homozygous for the F508del-CFTR Mutation. Expert Review of Precision Medicine and Drug Development, 1, 235-243.
https://doi.org/10.1080/23808993.2016.1175299
[6]  Cheng, P.C., Alexiou, S. and Rubenstein, R.C. (2019) Safety and Efficacy of Lumacaftor in Combination with Ivacaftor in Younger Patients with Cystic Fibrosis. Expert Review of Respiratory Medicine, 13, 417-423.
https://doi.org/10.1080/17476348.2019.1602040
[7]  Chlivers, M.A., Davies, J.C., Milla, C., Tian, S., Han, Z. and Cornell, A.G. (2021) Long-Term Safety and Efficacy of Lumacaftor-Ivacaftor Therapy in Children Aged 6-11 Years with Cystic Fibrosis Homozygous for the F508del-CFTR Mutation: A Phase 3, Open Label, Extension Study. The Lancet Respiratory Medicine.
https://doi.org/10.1016/S2213-2600(20)30517-8
[8]  Bulloch, M.N., Hanna, C. and Giovane, R. (2017) Lumacaftor/Ivacaftor, a Novel Agent for the Treatment of Cystic Fibrosis Patients Who Are Homozygous for the F508del-CFTR Mutation. Expert Review of Clinical Pharmacology, 10, 1055-1072.
https://doi.org/10.1080/17512433.2017.1378094
[9]  Pandiyan, P.J., Appadurai, R. and Ramesh, S. (2013) A High Throughput Analysis of Boronic Acids Using Ultra High-Performance Liquid Chromatography-Electrospray Ionization Mass Spectrometry. Analytical Methods, 5, 3386-3394.
https://doi.org/10.1039/c3ay40542g
[10]  Mullangi, S., Ravindhranath, K. and Panchakarla, R.K. (2021) LC–MS/MS Method for the Quantification of Potential Genotoxic Impurity 4-Phenoxyphenyl-Boronic Acid in Ibrutinib. Journal of the Iranian Chemical Society.
https://doi.org/10.1007/s13738-020-02118-3
[11]  Baldwin, A.F., North, R. and Eisenbeis, S. (2019) Trace Level Quantification of Derivatized Boronic Acids by LC-MS/MS. Organic Process Research & Development, 23, 88-92.
https://doi.org/10.1021/acs.oprd.8b00377
[12]  Schneider, E.K., Reyes-Ortega, F., Li, J. and Velkov, T. (2017) Optimized LC-MS/MS Method for the High Throughput Analysis of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients. Journal of Visualized Experiments, 128, e56084.
https://doi.org/10.3791/56084
[13]  Schneider, E.K., Reyes-Ortega, F., Wilson, J.W., et al. (2016) Development of HPLC and LC-MS/MS Method for the Analysis of Ivacaftor, Its Major Metabolites, and Lumacaftor in Plasma an Sputum of Cystic Fibrosis Patients Treated with ORKAMBI or KALYDECO. Journal of Chromatography B, 1038, 57-62.
https://doi.org/10.1016/j.jchromb.2016.10.026
[14]  Dastagiri, J., Sivagami, B., Chandrasekar, R., et al. (2019) Stability Indicating RP-HPLC Method for Simultaneous Estimation of Lumacaftor and Ivacaftor in Bulk and Pharmaceutical Dosage Form. Journal of Pharmaceutical Sciences & Research, 11, 2898-2904.
[15]  Gorantla, N., Dodlapati, J. and Jadi, S. (2019) A New Validated RP-HPLC Method for Simultaneous Estimation of Lumacaftor and Ivacaftor in Pharmaceutical Dosage Form. International Journal of Pharmaceutical Sciences Review and Research, 56, 30-37.
[16]  ICHQ2(R1) Validation of Analytical Procedures: Text and Methodology.
https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133